AstraZeneca Financial Results: Strong Revenue G...

By João L. Carapinha

February 11, 2026

AstraZeneca's financial results for FY and Q4 2025 showcased total revenue of $58.7 billion, up 8% at constant exchange rate...
KEYTRUDA Ovarian Cancer Treatments: FDA Approves New Regimens for Platinum-Re...
Advancements in Uncertainty-Aware Diagnostics with ConfiDx LLM
Enhancing Early-Stage Cancer Treatment: Overcoming Barriers for Better Outcomes
Launch of TrumpRx Drug Pricing: Savings on Essential Medications
Healthcare Innovation Trends Shaping the Future: Insights from the J.P. Morga...
AI Healthcare Costs: Navigating Financial Hurdles in Technology Integration
Datroway Metastatic Breast Cancer: FDA Grants Priority Review for Breakthroug...
FDA Confirms GLP-1 RA Safety Review: No Increased Suicidal Risk
Trump Economic Revival: Key Policies and Impacts from Davos 2026
Navigating Economic Resilience Through Life Sciences Investment
FDA Updates Labeling on Febrile Seizure Risks in Influenza Vaccine for Children
Guiding Principles for Ethical AI Integration in Drug Development